DUBLIN, April 20, 2018 /PRNewswire/ -- Iterum Therapeutics plc, a clinical-stage pharmaceutical company developing anti-infectives against multi-drug
Mini-Oral Presentation of ePoster 0736
Impact of Initial Inappropriate Antibiotic Therapy on Outcome for Uncomplicated Urinary Tract Infection Due to Antibiotic Non-Susceptible Enterobacteriaceae
The authors reviewed the records of 4,792 patients given oral antibiotics for uUTIs. Data on culture susceptibility, patients requiring a second antibiotic, and hospitalizations were recorded. They concluded:
Antimicrobial Activity of Sulopenem in the Urine of Healthy Volunteers
Impact of ESBL-Positivity and Quinolone Non-Susceptibility on Outcome for Inpatients with Complicated Urinary Tract Infections: A Multicenter Evaluation in the US
"The finding that one-in-five uncomplicated UTIs is caused by a multi-drug resistant pathogen is significant and instructive," said Dr. Michael Dunne, chief scientific officer at Iterum Therapeutics. "These and other data clearly show the need for new clinical approaches and therapies against resistant pathogens that are rendering traditional oral antibiotics ineffective."
"We believe sulopenem, which is being developed in oral and intravenous forms, has considerable potential as an important new treatment option to help patients and physicians better address infections caused by resistant pathogens."
Note to Editors:
About Iterum Therapeutics plc
Iterum Therapeutics plc (Iterum Therapeutics) is an Irish clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound with oral and IV formulations that has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received QIDP designations for its oral and IV formulations for the treatment of uUTI, cUTI and cIAI. Iterum Therapeutics is led by a highly experienced team and backed by a blue-chip venture capital syndicate. For more information, please visit http://www.iterumtx.com.
Media Contact:Stephen LedererStephen Lederer Communications860 501 firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/iterum-therapeutics-presents-data-on-prevalence-of-resistant-infections-and-activity-of-its-novel-antibiotic-sulopenem-300633214.html
SOURCE Iterum Therapeutics
Subscribe to our Free Newsletters!